



NATIONAL HEALTH COUNCIL

## ***Measuring Our Impact on Science, Delivery of Care, and Patient Outcomes***

**October 27-28, 2016**

Royal Sonesta Harbor Court Hotel  
550 Light Street  
Baltimore, Maryland 21202

### **Agenda**

#### **Thursday**

**2:00 p.m.**      **CMO, CSO & Research Directors Affinity Group Meeting**  
(2hr 30 min)      Tim Coetzee, PhD, Chief Advocacy, Services, and Research Officer, National Multiple Sclerosis Society, Affinity Group Chair

*Agenda TBD*

**6:00 p.m.**      **Opening Networking Reception**

**7:00 p.m.**      **Conference Welcome Dinner**

#### **Friday**

**7:00 a.m.**      **Breakfast Buffet**

**8:30 a.m.**      **Welcome and Conference Overview**  
Tim Coetzee, PhD, Chief Advocacy, Services, and Research Officer, National Multiple Sclerosis Society, and Conference Co-Chair

Kate Knobil, MD, Chief Medical Officer, Pharmaceuticals, GlaxoSmithKline, and Conference Co-Chair

**8:35 a.m.**      **Patient Engagement: Transforming the Science of Drug Development and Achieving Outcomes that Matter**

Morning Moderator: Kate Knobil, MD, Chief Medical Officer, Pharmaceuticals, GlaxoSmithKline, and Conference Co-Chair

**8:40 a.m.**      **Keynote:** Rob Califf, MD, Commissioner, US Food and Drug Administration

**9:10 a.m.**      **Moderated Panel Discussion: Deep dive into FDA's commitment to patient engagement**

- Theresa Mullin PhD, Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (invited);
- Jeffrey E. Shuren, MD, JD, Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Moderator: Kate Knobil, MD, Chief Medical Officer, Pharmaceuticals, GlaxoSmithKline

**10:00 a.m. Patient Engagement in Drug Development: Experiences, Good Practices, and Lessons Learned:**

*Representatives from patient groups and industry react to FDA session*

- Pat Furlong, Founding President, Parent Project Muscular Dystrophy;
- Sascha Haverfield, PhD, Senior Vice President, Scientific and Regulatory Affairs, PhRMA (invited);
- Lana Skirboll, PhD, Vice President, Science Policy, Sanofi

Moderator: Kate Knobil, MD, Chief Medical Officer, Pharmaceuticals, GlaxoSmithKline

**11:00 a.m. Breakout instructions and assignment**

**11:05 a.m. Networking Break**

**11:20 a.m. Breakout Session**

**12:05 p.m. Luncheon & Report out**

Luncheon Moderator: Michael Rosenblatt, Chief Medical officer, Flagship Ventures

**1:20 p.m. Afternoon Sessions**

Afternoon Moderator: Tim Coetzee PhD, Chief Advocacy, Services, and Research Officer, National Multiple Sclerosis Society, and Conference Co-Chair

**1:25 p.m. Scientific Breakthroughs: Celebrating Success While Managing Expectations**

- Lucie Bruijn, PhD, Chief Scientist, ALS Association;
- Steve Kolb, ALS Patient Caregiver;
- Allan L. Willard, PhD, Acting Deputy Director, National Institute of Neurological Disorders and Stroke (NINDS)

*Discussion with audience and presenters*

**2:40 p.m. Networking Break**

**3:00 p.m. Moderated Panel Discussion: Patient Engagement and the Assessment of Value**

- Cat Davis Ahmed, Director of Outreach, FH Foundation;
- Robert DuBois, EVP & Chief Medical Officer, National Pharmaceutical Council;
- Leah Howard, Director, Advocacy and Government Relations, National Psoriasis Foundation;
- Eleanor Perfetto, Sr. VP Strategic Initiatives, National Health Council

Moderator: Tim Coetzee, PhD, Chief Advocacy, Services, and Research Officer, National Multiple Sclerosis Society

**4:15 p.m. Looking to the Future: The Impact of Patient Engagement on Care Delivery and Outcomes**

Harold Paz, MD, Executive Vice President and Chief Medical Officer, Aetna

*Question and answer session with presenter*

**4:50 p.m.**

**Closing Remarks**

Tim Coetzee, PhD, Chief Advocacy, Services, and Research Officer, National Multiple Sclerosis Society, and Conference Co-Chair, and

Kate Knobil, MD, Chief Medical Officer, Pharmaceuticals, GlaxoSmithKline, and Conference Co-Chair

**5:00 p.m.**

**Adjourn**

DRAFT